Biden Administration Proposes Historic Move to Limit Nicotine in Cigarettes

US
Published:

The Biden administration is advancing a significant new proposal aimed at reducing smoking rates in the United States. On Wednesday, the U.S. Food and Drug Administration (FDA) announced a proposed rule that would limit nicotine levels in cigarettes and certain combusted tobacco products to minimally or non-addictive levels. If enacted, this regulation would make the U.S. the first country to adopt such a bold measure to curb smoking-related diseases.

This proposal comes as part of a long-term strategy to address tobacco use, which has been identified as a leading cause of preventable death in the nation. The FDA's initiative to lower nicotine levels was first introduced in 2018, and the agency is currently seeking public feedback as it enters the next stage of the rulemaking process.

FDA Commissioner Robert Califf stated, "Today’s proposal envisions a future where it would be less likely for young people to use cigarettes and more individuals who currently smoke could quit or switch to less harmful products." The proposed rule seeks to cap nicotine levels at 0.7 milligrams per gram of tobacco, well below the current average concentration.

However, the proposal has drawn criticism from some experts who believe it could inadvertently benefit illegal cigarette markets. Former Bureau of Alcohol, Tobacco, Firearms and Explosives assistant director Rich Marianos warned that organized crime could exploit the situation by supplying higher-nicotine cigarettes through illicit channels.

The FDA emphasizes that the proposed rule does not outright ban cigarettes but aims to make them less addictive. This initiative aligns with President Biden's broader public health goals, including prior efforts to eliminate menthol cigarettes as part of the Cancer Moonshot initiative.

The feedback period from the public will be critical as the FDA continues to address the complex issues surrounding tobacco regulation in the U.S.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US